Alprostadil

What is Alprostadil?

Alprostadil is not a peptide — it is a synthetic, pharmaceutical-grade form of prostaglandin E1 (PGE1), a 20-carbon eicosanoid lipid derived from arachidonic acid. It is included on Peptide List because the term 'alprostadil peptide' is a common search query among men exploring erectile-dysfunction therapies and parents of newborns with ductus-dependent congenital heart disease, and those readers deserve a clear correction: prostaglandins are lipid signaling molecules built from a cyclopentane ring with two unsaturated side chains and a terminal carboxylic acid, not chains of amino acids linked by peptide bonds. The molecular formula is C20H34O5 with a molecular weight of approximately 354 g/mol, vastly smaller than even short therapeutic peptides. Alprostadil is FDA-approved in two distinct contexts: (1) as Caverject (Pfizer/Pharmacia, approved 1995) and Edex (Endo Pharmaceuticals, approved 1997) for intracavernosal injection in erectile dysfunction; as Muse (Vivus, approved 1996) as a transurethral suppository; and as Vitaros (Ferring) as a topical intra-meatal cream approved in Europe and Canada (not currently US-marketed); and (2) as Prostin VR (Pfizer) for intravenous infusion in neonates to maintain patency of the ductus arteriosus in infants with ductus-dependent cyanotic congenital heart disease pending corrective surgery. Both indications exploit the same core pharmacology — vasodilation and smooth-muscle relaxation via prostaglandin-receptor signaling — applied to two utterly different anatomical targets.

What Alprostadil Is Investigated For

Alprostadil has two well-established FDA-approved use cases that share a mechanism (smooth-muscle relaxation via prostaglandin-receptor cAMP signaling) but apply it to entirely different patients. The erectile-dysfunction evidence is robust and decades deep: Linet and Ogrinc's NEJM 1996 trial established intracavernosal alprostadil as effective in roughly 87% of men with ED across multiple etiologies, Padma-Nathan's NEJM 1997 trial established the transurethral Muse formulation, and the European Alprostadil Study Group's long-term safety data (Br J Urol 1998) and Brock and Linet's Caverject long-term follow-up (Urology 2001) confirmed sustained efficacy with a return-of-spontaneous-erection signal in a meaningful subset of patients. The 2018 AUA Erectile Dysfunction Guideline and 2025 Papadopoulos meta-analysis position intracavernosal alprostadil as a second-line therapy after oral PDE5 inhibitors fail. The pediatric cardiology use case rests on equally foundational evidence: Olley and Coceani's 1976 Circulation paper opened the door, and Freed/Heymann/Lewis's 1981 cooperative study established PGE1 as the standard of care for maintaining ductal patency in cyanotic congenital heart disease — a use that has saved tens of thousands of newborns awaiting surgery. The honest synthesis: alprostadil is not a wellness or longevity drug, has no role in 'peptide stack' protocols despite being commonly mislabeled, and is best understood as an FDA-regulated medical therapy used under physician supervision in two specific clinical contexts.

History & Discovery

Prostaglandins were first identified in the 1930s, when Swedish physiologist Ulf von Euler isolated bioactive lipids from human seminal fluid that lowered blood pressure and contracted smooth muscle, naming them after the prostate gland (he initially believed the prostate was the source). Structural elucidation of the prostaglandin family had to wait three decades for the work of Sune Bergström and Bengt Samuelsson at the Karolinska Institute, who in the 1960s isolated and characterized the major prostaglandin species — including PGE1 — from sheep vesicular glands. In parallel, John Vane in London worked out the mechanism by which aspirin and related drugs inhibited prostaglandin synthesis via cyclooxygenase. Bergström, Samuelsson, and Vane shared the 1982 Nobel Prize in Physiology or Medicine for these discoveries — the foundation of an entire branch of lipid pharmacology. The clinical applications of PGE1 emerged in the 1970s. The pediatric-cardiology indication came first: Peter Olley and Flavio Coceani at the Hospital for Sick Children in Toronto, working on ductus arteriosus physiology, demonstrated in a series of papers culminating in the landmark 1976 Circulation publication that intravenous PGE could keep the ductus open in newborns with cyanotic congenital heart disease, providing a critical bridge to surgical repair. Michael Heymann, Abraham Rudolph, and colleagues at UCSF independently established the same principle, and the multicenter cooperative study published by Freed, Heymann, and Lewis in Circulation 1981 codified PGE1 as the standard of care. The Upjohn Company developed the pharmaceutical formulation as Prostin VR — the brand still marketed today (now under Pfizer following the Pharmacia and Upjohn corporate lineage). The erectile-dysfunction indication emerged later, building on Ronald Virag's 1982 demonstration that intracavernosal injection of vasoactive drugs could produce erections, and on a series of self-experimentation papers most famously by Giles Brindley, who in 1983 demonstrated intracavernosal phentolamine and papaverine on the lecture stage at an American Urological Association meeting. Researchers tested various intracavernosal vasodilators through the 1980s; alprostadil emerged as the most reliable single agent because of its potent, predictable, locally confined effect and rapid metabolic clearance. The pivotal Linet and Ogrinc trial published in NEJM 1996 demonstrated 87% efficacy across ED etiologies and supported FDA approval of Caverject (Upjohn) in 1995. Endo Pharmaceuticals followed with Edex in 1997, providing a dual-chamber cartridge that simplified reconstitution. The needle-free transurethral system Muse (Vivus) was approved in 1996 based on the Padma-Nathan NEJM 1997 trial. Vitaros, a topical intra-meatal cream developed by Nexmed and later licensed to Ferring, was approved in Canada and Europe in the early 2010s but failed multiple US filings on regulatory grounds (manufacturing and bioequivalence questions) and remains unavailable in the US market. Following the 1998 launch of sildenafil (Viagra) and subsequent oral PDE5 inhibitors, the ED-market position of alprostadil shifted from first-line to second-line therapy — a position it retains in the 2018 AUA guideline and the 2025 Papadopoulos meta-analysis. Its enduring clinical role rests on the fact that PDE5 inhibitors require intact NO-cGMP signaling, which is impaired in roughly 30-40% of severe ED cases (especially post-radical-prostatectomy and severe diabetic neuropathy) — alprostadil's cAMP-mediated mechanism remains effective when the NO pathway has failed. The pediatric cardiology indication has remained essentially unchanged in clinical importance for nearly 50 years, and Prostin VR is included on the WHO Essential Medicines List for newborns.

How It Works

Alprostadil is not a peptide — prostaglandins are not made of amino acids. It is a fatty-acid-derived signaling molecule (a lipid) that copies the action of prostaglandin E1 your body naturally produces. When it reaches smooth-muscle cells in blood vessels — whether in the penis or in a newborn's ductus arteriosus — it docks into prostaglandin E receptors on the cell surface and tells the cell to relax. That relaxation lets the local vessels open, blood flows in, and the tissue does what it is supposed to do: produce an erection in adult men, or keep a critical fetal blood-vessel shortcut open in newborns with certain heart defects.

Alprostadil is the synthetic, pharmaceutical-grade form of prostaglandin E1 (PGE1), one of the eicosanoid lipid mediators derived from the 20-carbon polyunsaturated fatty acid dihomo-gamma-linolenic acid via cyclooxygenase enzymes. Structurally it is built around a cyclopentane ring with a hydroxyl substituent and a ketone, flanked by two unsaturated side chains, one terminating in a carboxylic acid and the other in a hydroxylated alkyl tail. There are no amino acids, no peptide bonds, and no protein-folding chemistry — this is a small lipid (MW ~354 g/mol), categorically distinct from the peptide therapeutics this site otherwise covers. Biologically, PGE1 signals through four G-protein-coupled prostaglandin E receptors: EP1, EP2, EP3, and EP4. EP2 and EP4 are Gs-coupled and elevate intracellular cyclic AMP via adenylyl cyclase activation; EP1 is Gq-coupled and elevates intracellular calcium; EP3 has multiple splice variants and predominantly Gi-couples to lower cAMP. The dominant effect of alprostadil in the indications for which it is FDA-approved is mediated by EP2 and EP4 activation, raising cAMP, activating protein kinase A, opening ATP-sensitive and calcium-activated potassium channels, hyperpolarizing the cell membrane, closing voltage-gated calcium channels, lowering intracellular calcium, and ultimately relaxing vascular and visceral smooth muscle. In the male erectile context, intracavernosal injection (or urethral or topical absorption) delivers alprostadil directly to corpus cavernosum smooth muscle. EP-receptor-mediated cAMP elevation relaxes the cavernosal trabecular smooth muscle, the sinusoidal spaces dilate, arterial inflow rises, the engorged sinusoids mechanically compress the subtunical venous plexus against the unyielding tunica albuginea, venous outflow drops, and a rigid erection develops. This pathway operates independently of the nitric oxide / cGMP / PDE5 axis that oral PDE5 inhibitors target, which is why alprostadil retains efficacy in patients with neurogenic ED, severe vascular ED, or post-radical-prostatectomy ED in whom PDE5 inhibitors have failed. In the neonatal cardiac context, the ductus arteriosus — a fetal vessel connecting the pulmonary artery to the aorta that normally closes after birth as PGE2 levels fall — is held open by continuous IV infusion of alprostadil. The ductus is exquisitely sensitive to prostaglandin E signaling; EP4 receptors on ductal smooth muscle, working through the same cAMP-protein kinase A-potassium-channel pathway, prevent the postnatal contraction and remodeling that closes the vessel. Waleh and Clyman's 2004 Circulation paper documented the gestational-age-dependent expression of EP receptors on the ductus, providing the molecular basis for the well-known clinical observation that PGE1 responsiveness is higher in younger and more premature ductal tissue. Pharmacokinetically, alprostadil is rapidly metabolized — its plasma half-life is approximately 30 seconds to 10 minutes depending on tissue and route. After IV administration, roughly 60-80% of a dose is cleared by a single pulmonary first pass via beta-oxidation. This very rapid clearance is the reason continuous IV infusion is required for the neonatal indication and the reason that intracavernosal or intraurethral local delivery — which bypasses systemic clearance — is necessary for the erectile indication. Hepatic metabolism is minor; renal excretion of metabolites is the primary elimination route. Because clearance is enzymatic rather than CYP-mediated, classic CYP-based drug interactions are not a major concern, though pharmacodynamic interactions with other vasodilators (PDE5 inhibitors, alpha-blockers) and with antihypertensives are clinically relevant.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Alprostadil:

• 01Long-term outcomes (15+ years) of repeated intracavernosal alprostadil — observational follow-up exists, but no formal long-term registry tracks fibrosis, cumulative dose, and erectile-function trajectory in detail.
• 02US regulatory pathway for Vitaros topical cream — the cream is approved and used in Europe and Canada, but multiple US submissions have failed on manufacturing and bioequivalence grounds; whether a future filing will succeed is unclear.
• 03Optimal combination protocols ('trimix' alprostadil + papaverine + phentolamine, 'bimix' alprostadil + phentolamine) are widely used off-label by compounding pharmacies, but high-quality randomized comparisons against single-agent alprostadil are limited.
• 04Long-term neurodevelopmental outcomes in neonates receiving extended PGE1 infusion (days to weeks) before cardiac surgery are confounded by the underlying cardiac diagnosis and have not been independently isolated.
• 05Pediatric dosing optimization — the standard 0.05-0.1 mcg/kg/min infusion has been clinical practice for decades, but dose-finding studies in the modern era of pulse oximetry and echocardiographic monitoring are limited.
• 06Topical and intra-meatal absorption pharmacokinetics — meta-analyses (Papadopoulos 2025) confirm efficacy but the underlying absorption variability, partner-exposure risk, and optimal application protocol remain incompletely characterized.
• 07Role in post-radical-prostatectomy penile rehabilitation — protocols recommending early scheduled alprostadil (with or without PDE5 inhibitor) to preserve cavernosal smooth muscle integrity exist, but optimal timing, dose, and duration have not been definitively established.

Forms & Administration

Alprostadil is supplied in four distinct prescription formulations corresponding to its two main indications. (1) Intracavernosal injection: Caverject (Pfizer, single-dose vial reconstituted, 5-40 mcg per injection) and Edex (Endo, dual-chamber cartridge, 10-40 mcg) are injected by the patient or partner directly into the corpus cavernosum using a short (1/2 inch) 27-30 gauge needle, with dose titrated by a urologist to achieve a 30-60 minute erection. (2) Transurethral suppository: Muse (Vivus, 125-1000 mcg pellet) is inserted via a single-use applicator into the distal urethra after urination; absorption through the urethral mucosa to corpus spongiosum and then by venous communication to corpora cavernosa produces an erection in 5-10 minutes. (3) Topical intra-meatal cream: Vitaros (Ferring, 300 mcg per dose in a single-use applicator) is applied to the urethral meatus 5-30 minutes before intercourse — approved in the EU, UK, and Canada; not currently US-marketed. (4) Intravenous infusion: Prostin VR Pediatric (Pfizer, 500 mcg/mL ampule) is diluted and infused continuously at 0.05-0.1 mcg/kg/min in neonates with ductus-dependent congenital heart disease, titrated to maintain ductal patency until surgical correction; this is administered only in NICU or pediatric cardiac ICU settings with continuous respiratory and hemodynamic monitoring. All four formulations are prescription-only and require physician initiation and oversight; none are appropriate for casual or self-experimentation use.

Common Questions

Who Alprostadil Is NOT For

Drug & Supplement Interactions

Alprostadil is metabolized primarily by enzymatic beta-oxidation (predominantly during a single pulmonary first pass after IV administration) rather than by hepatic cytochrome P450 enzymes, so classical CYP-mediated pharmacokinetic interactions are not a major concern. The dominant interactions are pharmacodynamic. For erectile-dysfunction indications, concurrent use with oral phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) is not formally contraindicated but combination has been associated with prolonged erection and priapism in case reports. Most urologists advise patients to use only one ED therapy at a time and to wait for full clearance of the oral PDE5 inhibitor before resorting to intracavernosal alprostadil. Concurrent alpha-adrenergic blockers (used for benign prostatic hyperplasia or hypertension) can additively lower blood pressure and increase syncope risk, particularly with the topical and transurethral formulations. Sympathomimetic decongestants and vasoconstrictors theoretically counteract alprostadil's local vasodilatory effect; phenylephrine is in fact the first-line treatment for alprostadil-induced priapism, given via intracavernosal injection. For neonatal IV infusion, the dominant pharmacodynamic interactions involve other vasodilators and respiratory depressants. Concurrent diuretics may amplify hypotension. Concurrent opioids or sedatives may compound the apnea risk inherent to PGE1 infusion. Indomethacin and other COX inhibitors directly antagonize alprostadil's mechanism by reducing endogenous prostaglandin production; this is clinically relevant because indomethacin is sometimes used to close a patent ductus in the opposite clinical scenario, and the two drugs should never be co-administered. Anticoagulants (warfarin, heparin, DOACs) and antiplatelets (aspirin, clopidogrel) can increase the risk of cavernosal bleeding and hematoma with intracavernosal injection; patients on full-dose anticoagulation should discuss this risk with their urologist and may be better candidates for the transurethral or topical formulations. As always, the operative reference for specific interaction guidance is the institutional protocol and current FDA prescribing information, not this summary.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions